期刊
ACTA PHARMACEUTICA SINICA B
卷 5, 期 3, 页码 188-193出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2015.01.011
关键词
EZH2; Human colon cancer HCT116 cells; DZNep; Anti-cancer mechanisms
资金
- Sino-Singapore Collaboration Project from the Ministry of Science and Technology (MOST) of China [2013DFG32990]
- National Natural Science Foundation of China (NSFC) [81373438, 31201040]
- National Mega-Project for Innovative Drugs by MOST [2012ZX09301002-001-015]
EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation, metastasis and poor prognosis. Targeting and inhibiting EZH2 may he an effective therapeutic strategy for colon cancer. 31Deazaneplanocin A (DZNeN, as an EZH2 inhibitor, can suppress cancer cell growth. However, the anti-cancer role of DZNep in colon cancer cells has been rarely studied. In this study, we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis. The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据